Towards standardization of F-18-FET PET imaging: do we need a consistent method of background activity assessment? by Unterrainer, Marcus et al.
ORIGINAL RESEARCH Open Access
Towards standardization of 18F-FET PET
imaging: do we need a consistent method
of background activity assessment?
Marcus Unterrainer1,2, Franziska Vettermann1, Matthias Brendel1, Adrien Holzgreve1,3, Michael Lifschitz1,
Matthias Zähringer1, Bogdana Suchorska3, Vera Wenter1, Ben M. Illigens2,4, Peter Bartenstein1
and Nathalie L. Albert1*
Abstract
Background: PET with O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) has reached increasing clinical significance for
patients with brain neoplasms. For quantification of standard PET-derived parameters such as the tumor-to-
background ratio, the background activity is assessed using a region of interest (ROI) or volume of interest (VOI) in
unaffected brain tissue. However, there is no standardized approach regarding the assessment of the background
reference. Therefore, we evaluated the intra- and inter-reader variability of commonly applied approaches for
clinical 18F-FET PET reading.
The background activity of 20 18F-FET PET scans was independently evaluated by 6 readers using a (i) simple
2D-ROI, (ii) spherical VOI with 3.0 cm diameter, and (iii) VOI consisting of crescent-shaped ROIs; each in the
contralateral, non-affected hemisphere including white and gray matter in line with the European Association of
Nuclear Medicine (EANM) and German guidelines. To assess intra-reader variability, each scan was evaluated 10
times by each reader. The coefficient of variation (CoV) was assessed for determination of intra- and inter-reader
variability. In a second step, the best method was refined by instructions for a guided background activity
assessment and validated by 10 further scans.
Results: Compared to the other approaches, the crescent-shaped VOIs revealed most stable results with the
lowest intra-reader variabilities (median CoV 1.52%, spherical VOI 4.20%, 2D-ROI 3.69%; p < 0.001) and inter-reader
variabilities (median CoV 2.14%, spherical VOI 4.02%, 2D-ROI 3.83%; p = 0.001). Using the guided background
assessment, both intra-reader variabilities (median CoV 1.10%) and inter-reader variabilities (median CoV 1.19%)
could be reduced even more.
Conclusions: The commonly applied methods for background activity assessment show different variability which
might hamper 18F-FET PET quantification and comparability in multicenter settings. The proposed background
activity assessment using a (guided) crescent-shaped VOI allows minimization of both intra- and inter-reader
variability and might facilitate comprehensive methodological standardization of amino acid PET which is of
interest in the light of the anticipated EANM technical guidelines.
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Background
PET with O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) has
reached increasing clinical significance for the workup of
patients suffering from brain neoplasms as an additional
and highly valuable imaging tool. As recently emphasized
by the RANO working group [1], clinical applications of
18F-FET PET are represented by, e.g., treatment planning
[2], patient monitoring [3], prognostication at initial diag-
nosis [4, 5], and evaluation of pseudoprogression [6].
Particularly, PET parameters such as the maximal tumor-
to-background-ratio (TBRmax) are used in clinical routine,
e.g., for response assessment of alkylating and antiangio-
genic agents [7–9] or differentiation of viable tumor from
treatment-related changes [10–13].
For evaluation of 18F-FET PET parameters, a
background-activity reference in unaffected brain tissue
is used to enable intra- and inter-individual compar-
ability of PET results. The European Association of
Nuclear Medicine (EANM) guideline for brain tumor
imaging stated “Interpretation of quantitative results is
based on the comparison of tumor-to-background
uptake ratio,” and although the guideline pointed to a
potential source of error by “small regional differences
in uptake in normal brain, emphasizing the need for care-
ful choice of an appropriate reference region” [14], there is
no procedural recommendation regarding the method of
background assessment. Therefore, several different and
inconsistent approaches for background assessment are
used in the current literature and in the clinical routine:
one approach uses a region of interest (ROI) in the
contralateral hemisphere including white and gray matter
[15, 16], which is in line with the German guideline for
amino acid imaging, which stated that a ROI should be
placed in unaffected contralateral brain tissue, “e.g., with a
diameter of 50 mm” [17]. Other approaches apply
volumes-of-interest (VOI) including gray and white mat-
ter, i.e., a spherical VOI with a diameter of 30 mm [18, 19]
or a VOI consisting of crescent-shaped ROIs [13, 20]. Al-
though first suggestions were made regarding a software-
based assessment using [11C]-methionine PET previously
[21], there is still no standardized and consistent proced-
ure used in the clinical routine.
Hence, we intended to elucidate the effects of different
approaches for background activity assessment and to
evaluate simple and clinically applicable methods of back-
ground activity assessment for 18F-FET PET imaging re-
garding their inter- and intra-reader variability in the light
of an emphasized comprehensive standardization of amino
acid PET.
Methods
PET acquisition and data evaluation
Dynamic 18F-FET PET scans were acquired with an
ECAT Exact HR+ scanner (Siemens, Erlangen, Germany)
according to standard protocols [22], after a fasting
period of at least 6 h prior to PET scanning. After a 15-
min transmission scan with a 68Ge rotating rod source,
approximately 180 MBq of 18F-FET were injected as an
intravenous bolus. Afterwards, the 40-min dynamic
emission recording in 3-D mode consisting of 16
frames (7 × 10 and 3 × 30 s; 1 × 2, 3 × 5, and 2 × 10 min)
was started. Images corrected for attenuation and scatter
were reconstructed by filtered back-projection using a 5-
mm Hann filter. For conventional semi-quantitative evalu-
ation, the maximal tumoral 18F-FET uptake (SUVmax) was
determined on a summation image (20–40 min after
injection). The biological-tumor-volume (BTV) was
estimated by semiautomatic calculation of a VOI using
a threshold of TBR ≥ 1.6, previously proposed as opti-
mal threshold for differentiation of tumor and sur-
rounding healthy tissue [23]. 18F-FET PET was evaluated
on a Hermes workstation (Hermes Medical Solutions,
Stockholm, Sweden) as described previously [22].
18F-FET PET scans
Twenty 18F-FET PET scans of patients with histologically
proven glioma were randomly selected for background ac-
tivity assessment. In a second step, a randomly selected
control cohort including 10 additional 18F-FET PET scans
was used to assess the guided background assessment on
an intra-individual and inter-individual basis. All patients
gave written consent to undergo 18F-FET PET as part of
the clinical routine. The retrospective study was approved
by the local ethical review board.
Readers and background activity assessment
Six readers performed an evaluation of the following
three methods of background activity assessment in all
20 scans according to the following instructions:
1. Simple ROI: A single 2D-ROI in the contralateral
hemisphere including white and gray matter (e.g.,
50 mm diameter), as proposed in the German
guideline [17].
2. Spherical VOI: A spherical VOI with a diameter
of 30 mm in the contralateral hemisphere including
white and gray matter, as published previously
[18, 19].
3. Crescent-shaped VOI: A merged VOI consisting
of six crescent-shaped ROIs in the contralateral
hemisphere including white and gray matter as
published previously [13, 20].
To evaluate the intra-reader variability of each method,
each reader independently evaluated the row of 20 scans
for 10 times (a methodologic outline is shown in Fig. 1,
examples of the different approaches are displayed in
Fig. 2). Of the 6 readers, 3 were experienced (M.U., F.V.,
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M.B.; each with >500 clinical 18F-FET PET reads) and 3
unexperienced (A.H., M.L., M.Z.) in the clinical reading of
18F-FET PET scans.
In a second step, the best method of the first study
part was applied in additional 10 control scans. In
analogy to the first evaluation, the additional scans were
analyzed by each reader independently and repeatedly
(10 times). As amendment, the readers were prompted
to use standardized instructions for guidance and preci-
sion of background assessment in order to reduce inter-
individual variability (see Fig. 3).
Statistics
Statistical analyses were performed with IBM® SPSS®
Statistics, Version 23. As standardized measure of dis-
persion, the “coefficient of variation” (CoV), defined as
ratio of the standard deviation to the mean, was applied
to assess the intra-reader variability (individual CoV of a
particular scan) as well as the inter-reader variability
(CoV of the mean SUV values of the six readers regard-
ing a particular scan). Normal distribution was assessed
using the Shapiro-Wilk test. The intra- and inter- indi-
vidual CoVs of the different reference approaches were
compared using the non-parametric Friedman-/Kruskal-
Wallis test and the paired/unpaired Mann-Whitney U
test, respectively. Statistical significance was defined as
two-tailed p values below 0.05.
Results
Simple ROI
When applied in all readers, the use of a simple ROI in the
contralateral hemisphere showed a median intra-individual
variability of a CoV of 3.69% (range 1.90–7.05%) with a
homogenous distribution throughout all 6 readers. When
comparing the individual mean SUV-measurements in all
20 scans, a median variability (inter-reader CoV) of 3.83%
(range 1.80–7.46%) could be observed (see Table 1).
There was no statistically different intra-reader vari-
ability between experienced and unexperienced readers
(3.15% (1.95–6.23%) vs. 3.69% (1.90–7.05%), p = 0.087).
Experienced readers showed a significantly smaller
Fig. 1 Procedural outline. a Evaluation of three commonly used methods for background assessment, b evaluation of the best method of a with
additional guidance through instructions
Fig. 2 Examples of the different methods of background assessment. a T1 MRI for morphological correlation. The three different methods of
background activity assessment are featured using b a 2D-ROI in the contralateral hemisphere with 5 cm diameter as example (as suggested
in the German guideline), c a spherical VOI with 3 cm diameter, and d a crescent-shaped VOI approach
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variability in terms of inter-reader variability (1.63%
(0.05–5.00%) vs. 4.37% (0.59–5.37%), p = 0.001).
Spherical VOI
The approach using a spherical VOI showed comparable
intra-reader variabilities with a median CoV of 4.20%,
but provided an even broader CoV range (1.74–8.30%)
(see Table 1). When comparing the mean SUV values
between the 6 readers, a median inter-reader CoV of
4.02% with a relatively broad range throughout the 20
included scans could be observed (range 1.47–6.32%).
Experienced readers provided a significantly smaller
intra-reader variability (median CoV 3.22% (1.74–
5.98%) vs. 4.63% (2.58–8.30%); p < 0.001), whereas no
significant difference (2.16% (0.61–5.63%) vs. 2.71%
(0.59–5.37%), p = 0.970) in terms of inter-reader vari-
ability between experienced and unexperienced could
be observed.
Crescent VOI
The use of crescent-shaped VOIs for background activity
assessment revealed a median intra-individual CoV of
1.52% (range 0.48–3.78%). Although the median inter-
rater CoV was low with a value of 2.14%, there were
some scans with outlining inter-reader variabilities of up
to 7% (range 1.05–7.23%).
Experienced readers revealed a significantly smaller
intra-reader variability (median CoV 1.20% (0.39–
2.42%) vs. 1.81% (0.55–3.78%); p < 0.001), whereas no
significant difference in terms of inter-reader variability
could be observed between experienced and unexper-
ienced readers (median CoV 1.36% (0–6.13%) vs. 1.97%
(0.63–9.57%), p = 0.537).
Comparison of background assessment methods
All six readers obtained the most stable background ac-
tivity values at the lowest median intra-reader CoV by
the use of the crescent-shaped VOI when compared to
the simple ROI (p < 0.001 in each reader) or the spher-
ical VOI (p < 0.001 in each reader). Additionally, the
crescent-VOI approach revealed the significantly lowest
inter-reader variability as well when compared to the
other methods (p = 0.001; see also Table 1).
Background activity assessment using the guided
crescent-shaped VOI
In the guided approach using the clearly defined in-
structions, the inter-reader variability could be signifi-
cantly reduced to a median CoV of 1.19% (range 0.84–
1.89%, p = 0.001) with a considerably smaller range
compared to the unguided approach (see Table 2).
Furthermore, the median intra-reader variability was
1.10% (range 0.52–2.36%), which was significantly
lower (p < 0.001) than the unguided crescent-VOI
approach.
No statistically different median CoV between experi-
enced and unexperienced readers (1.01% (0.70–1.75%)
vs. 1.20% (0.52–2.36%), p = 0.060) could be detected
using the guided VOI approach regarding intra-reader
variability. Nonetheless, experienced readers showed a
smaller variability in terms of inter-reader variability
(0.63% (0–1.39%) vs 1.42% (0–2.88%), p = 0.037) when
compared to the unexperienced readers.
Table 1 Intra- and inter-reader coefficients of variation using VOI/ROIs [median (range)]
Simple ROI Spherical VOI Crescent VOI Friedman test
Intra-reader variabilities
Overall group 3.69% (1.90–7.05%) 4.20% (1.74–8.30%) 1.52% (0.48–3.78%) p < 0.001
Reader #1 4.03% (1.90–7.05%) 4.83% (2.58–8.30%) 1.04% (0.55–3.00%) p < 0.001
Reader #2 5.16% (2.37–6.23%) 4.38% (2.79–5.98%) 1.49% (0.97–2.25%) p < 0.001
Reader #3 2.86% (2.07–5.38%) 2.72% (1.74–3.53%) 1.19% (0.48–2.27%) p < 0.001
Reader #4 2.99% (2.23–4.20%) 3.97% (2.59–6.68%) 2.06% (1.11–2.75%) p < 0.001
Reader #5 2.62% (1.95–4.06%) 3.09% (2.02–5.04%) 1.05% (0.39–2.42%) p < 0.001
Reader #6 4.74% (2.42–6.96%) 5.46% (3.04–6.57%) 1.97% (1.07–3.78%) p < 0.001
Inter-reader variabilities
Overall group 3.83% (1.80–7.46%) 4.02% (1.47–6.32%) 2.14% (1.05–7.23%) p = 0.001
Fig. 3 Instruction for the guided, crescent-shaped VOI approach
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Discussion
Complementary to MRI, 18F-FET PET has gained clin-
ical importance for the diagnostic workup of brain
tumor patients in all disease stages, as recently recom-
mended by the RANO and EANO working group [1].
However, the methods of PET evaluation are not yet
standardized. In particular, the approaches for background
activity assessment are variable, although background
assessment is essential for the evaluation of TBR values as
well as quantification of biological tumor volume. For the
implementation of 18F-FET PET into clinical trials, a
methodological PET standardization is urgently needed to
enable more precise and reproducible 18F-FET PET
quantification.
Looking at the present data it can be stated that the
different approaches under investigation show a certain
variability on an intra-individual as well as on an inter-
individual basis with expectable background SUV changes
up to ±8% (which means a notable dispersion of up to
16%) and might therefore be considered as potential
source of methodological error besides known influencing
factors such as different reconstruction algorithms and
diverging PET scanners.
When evaluating the different background assessment
approaches, the use of a single ROI showed a relatively
high intra- and inter-reader variability; this might be due
to the assessment of a relatively small regional part of
unaffected brain only (ROI vs. VOI in the other ap-
proaches) as well as unprecise description regarding
shape and spatial localization, as ambiguously stated in
the German guideline for amino-acid PET (“[…] a larger
background ROI in the contralateral and unaffected
hemisphere including gray and white matter (diameter,
e.g., 50 mm)”) [17].
Although the application of a spherical VOI with a
fixed diameter of 3 cm represents a uniform approach
without individual changes regarding the shape of the
VOI, this approach likewise showed a relatively high
variability; the rigid shape did not necessarily lead to
high stability of SUV measurement since areas inappro-
priate for background assessment might be included
inevitably due to individual morphologic properties, e.g.,
the ventricular system.
In comparison to these two approaches, the use of
crescent-shaped VOIs provided both the lowest intra-
reader and inter-reader variability. An advantage of this
approach might be the possible adaption of the individ-
ual morphologic properties. Nonetheless, some single
outlining scans with an inter-reader CoV up to 7% oc-
curred in our analysis, most likely due to a differing
localization of the six sequential crescent-shaped ROIs
in different brain areas with slightly different back-
ground activities throughout the six readers. This can
be stated since the variabilities were very small within
single readers, leading to the assumption that every sin-
gle reader had a constant method of manual VOI defin-
ition. Therefore, we consequently intended to guide the
manual defining of the crescent-shaped VOI to further
reduce the inter-reader variability using the instructions
described in the “Methods” section. These instructions
intended to provide a high standardization in terms of
shape and localization of the applied VOIs. Indeed, this
approach showed the lowest variability between the
readers with a median inter-reader CoV of 1.19% (range
0.84–1.89%) and therefore a maximum expectable
dispersion <4% regarding the background SUV. Inter-
estingly, this approach could additionally reduce the
individual intra-reader variabilities when compared to
the “unguided” crescent-VOI approach (1.10% (range
0.52–2.36%) vs. 1.52% (range 0.48–3.78%)). Besides, the
possibility of an adaption of the VOI shape according
to individual morphologic properties, an explanation
for the low variability of the crescent-shaped VOI
approach might be that the summation of six crescent-
shaped ROIs led to relatively large volumes, which
could also contribute to the higher stability. Further-
more, the crescent-shaped VOI is characterized by a
balanced inclusion of gray and white matter, while the
proportion and composition of included structures
might be more variable depending on the exact posi-
tioning of a ROI/VOI with a fix shape.
Although the overall variability might seem moderate at
first sight, it is important to note that there are outliners up
to a CoV of 8% when using the spherical approach. In clin-
ical routine, this leads to an expectable difference of up to
+8% as well as −8% of the background SUV. This would
not only lead to substantially different TBR values but also
to substantially different thresholds for the delineation of
the BTV, which is commonly defined by 1.6 × background
activity. For visualization, the maximal intra-reader as well
as inter-reader differences and their consequences on the
clinically important 18F-FET PET parameters are presented
in clinical examples (see Fig. 4).
Table 2 Intra- and inter-reader coefficients of variation using
the guided VOI [median (range)]
Intra-reader variabilities
Overall group 1.10% (0.52–2.36%)
Reader #1 1.06% (0.74–1.77%)
Reader #2 0.81% (0.66–0.99%)
Reader #3 1.06% (0.74–1.31%)
Reader #4 1.73% (1.13–2.36%)
Reader #5 1.00% (0.70–1.75%)
Reader #6 0.93% (0.52–1.57%)
Inter-reader variabilities
Overall group 1.19% (0.84–1.89%)
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In the clinical routine, high differences regarding the
TBR could substantially influence the conclusion of a PET
scan and thereby hamper the diagnostic value, e.g., when
used for differentiation of treatment-related changes and
viable tumor [11–13]. In particular, distinct cutoff values
for the evaluation of gliomas are used in clinical routine
[3, 10], e.g., the cutoff TBRmean ≥ 2.0 differentiates pro-
gressive disease from treatment-related changes with a
high accuracy. This is also true for the BTV evaluation,
e.g., when used for response-assessment during chemo-
therapy [7–9], where distinct changes of, e.g., 20% are
considered as treatment response and vice versa. Add-
itionally, besides the mere quantitative information of the
volumetric measure, the spatial localization and extent of
the tumor tissue, influenced by the background assess-
ment, might also have an impact on the clinical workup,
e.g., regarding radiotherapy planning [2, 24]. Nonetheless,
the interfering factor can considerably be reduced as
highlighted using the crescent-shaped VOI approach for
background activity assessment.
This is especially the case since the application of the
crescent-shaped VOI showed the lowest variabilities in
the subgroups of the experienced and unexperienced
readers in terms of both intra- and inter-reader vari-
ability. Additionally, the use of the detailed instructions
for a guided VOI could additionally reduce the variabil-
ity. It should be pointed out that possibly influencing
factors, such as “non-neoplastic” lesions (e.g., major in-
farctions in MRI, cysts), should not be included in the
background VOI.
Our results are of high interest with regard to multicen-
ter comparisons and anticipated multicenter studies,
which require a high degree of standardization in order to
provide reproducible and reliable PET data in all sites per-
forming amino acid imaging of brain tumors. Besides the
standardization of ordinary influencing factors such as re-
construction algorithms and PET scanner type, it will, ac-
cording to our results, be important to standardize the
particular method of background activity assessment.
Although a software-based method had already been
suggested for [11C]-methionine PET 10 years ago [21],
it is essential to find a quick and unpretentious, but re-
liable approach without any need of further hardware
or software solutions, which might be suitable for basic
research applications, but surely hamper the clinical
implementation. Within the commonly applied methods,
the crescent-shaped VOI assessment showed the lowest
variabilities even in unexperienced readers and the best
results were reached with simple instructions for a
guided VOI assessment. We therefore propose this
method as possible and clinically applicable approach
for methodological standardization, which is strongly
needed, since the current RANO/EANO recommenda-
tions for the clinical use of PET imaging in gliomas,
which were recognized very positively in the literature
[25, 26], emphasized the implementations of amino
acid PET in future prospective multicenter trials but
pointed out that “[…] numerous studies differed in
terms of methodology, which limits comparability of
data and might eventually jeopardize acceptance in the
clinical setting.” [1]. In the context of the anticipated
standardized technical guidelines for glioma PET im-
aging procedures and recommendations by the EANM,
EANO, and RANO [1], the use of a standardized ap-
proach for background activity assessment might be an
important methodological landmark.
Fig. 4 Influence of different background activity values on TBRmax and BTV values. a An example of a simple 2D-ROI assessment with measured
background SUV values between 1.17–1.50: the resulting TBRmax ranges between 3.10 and 4.01 (ΔTBRmax, 0.91; %ΔTBR, 29%), the BTV delineated
with the calculated lowest threshold of SUV 1.87 is 45.89 ml, while BTV using the threshold with the highest background SUV (threshold SUV
2.40) results in a BTV with 9.91 ml only (ΔBTV, 35.98 ml; %ΔBTV, 78%). b The guided VOI assessment with a maximal background SUV range of
0.83–0.87 results in a small TBR range of 2.99–3.13 (ΔTBRmax, 0.14; %ΔTBRmax, 4%) and a BTV range of 20.53–22.63 ml (ΔBTV, 2.10 ml; %ΔBTV, 9%)
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Conclusions
Among the commonly used methods for the assess-
ment of background activity in 18F-FET PET, the
(guided) crescent-shaped VOI in the contralateral
hemisphere reveals the most stable results and can sub-
stantially minimize both intra- and inter-reader variability.
It represents a quick and easily applicable approach for
the clinical routine, which might facilitate comprehensive
methodological standardization of amino acid PET evalu-
ation and strengthen its value in the clinical setting.
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